12:00 AM
May 12, 2014
 |  BioCentury  |  Emerging Company Profile

Inotrem: Sepsis companion

Inotrem banking on companion Dx to target TREM1 inhibitors in sepsis

Inotrem S.A. is betting that a companion diagnostic can help its TREM1 inhibitors tamp down inflammation in the right sepsis patients and improve its odds of success in an indication where the only approved drug was pulled from the market three years ago.

Sepsis is a systematic inflammatory response most often triggered by severe bacterial infection. A major challenge to treatment is the immune response itself, which is both toxic to the host and necessary to combat the infection. To improve survival, a treatment must strike a delicate balance between the two.

This balance has been hard to find, as numerous compounds have failed to demonstrate a survival benefit in the indication. In 2011, Eli Lilly and Co. withdrew Xigris drotrecogin from the market after the alfa recombinant human activated protein C failed a confirmatory Phase III trial.

Inotrem CEO Jean-Jacques Garaud said sepsis can behave differently depending on the cause of infection.

"One of the issues around sepsis which leads to clinical trial failures...

Read the full 816 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >